{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:02:12Z","timestamp":1793505732333,"version":"4.5.0"},"reference-count":174,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2019,9,1]]},"DOI":"10.1007\/s00018-019-03138-w","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T01:56:37Z","timestamp":1558058197000},"page":"3525-3542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":306,"title":["Antiviral peptides as promising therapeutic drugs"],"prefix":"10.1007","volume":"76","author":[{"given":"Liana Costa Pereira","family":"Vilas Boas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Lattarulo","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhayfa Lorrayne Araujo","family":"Berlanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natan","family":"de Carvalho Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9546-0525","authenticated-orcid":false,"given":"Oct\u00e1vio Luiz","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"key":"3138_CR1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/1751-7915.12397","volume":"9","author":"A Mahmoud","year":"2016","unstructured":"Mahmoud A (2016) New vaccines: challenges of discovery. Microb Biotechnol 9:549\u2013552. https:\/\/doi.org\/10.1111\/1751-7915.12397","journal-title":"Microb Biotechnol"},{"key":"3138_CR2","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1128\/jvi.00151-09","volume":"83","author":"LW Enquist","year":"2009","unstructured":"Enquist LW (2009) Virology in the 21st Century. J Virol 83:5296\u20135308. https:\/\/doi.org\/10.1128\/jvi.00151-09","journal-title":"J Virol"},{"key":"3138_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.tips.2013.11.006","volume":"35","author":"Z Lou","year":"2014","unstructured":"Lou Z, Sun Y, Rao Z (2014) Current progress in antiviral strategies. Trends Pharmacol Sci 35:86\u2013102. https:\/\/doi.org\/10.1016\/j.tips.2013.11.006","journal-title":"Trends Pharmacol Sci"},{"key":"3138_CR4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/archinte.1997.00440300037003","volume":"157","author":"CK McDonald","year":"1997","unstructured":"McDonald CK, Kuritzkes DR (1997) Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med 157:951. https:\/\/doi.org\/10.1001\/archinte.1997.00440300037003","journal-title":"Arch Intern Med"},{"key":"3138_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1146\/annurev-pharmtox-011112-140254","volume":"53","author":"JJ Kiser","year":"2013","unstructured":"Kiser JJ, Flexner C (2013) Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol 53:427\u2013449. https:\/\/doi.org\/10.1146\/annurev-pharmtox-011112-140254","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3138_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/v5010127","volume":"5","author":"F Yu","year":"2013","unstructured":"Yu F, Lu L, Du L et al (2013) Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket. Viruses 5:127\u2013149","journal-title":"Viruses"},{"key":"3138_CR7","doi-asserted-by":"publisher","first-page":"10069","DOI":"10.5812\/hepatmon.10069","volume":"13","author":"M El Raziky","year":"2013","unstructured":"El Raziky M, Fathalah WF, El-Akel WA et al (2013) The effect of peginterferon Alpha-2a vs. Peginterferon Alpha-2b in treatment of naive chronic HCV genotype-4 patients: a single centre Egyptian study. Hepat Mon 13:10069. https:\/\/doi.org\/10.5812\/hepatmon.10069","journal-title":"Hepat Mon"},{"key":"3138_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","volume":"25","author":"Lin Fching","year":"2014","unstructured":"Fching Lin, Young HA (2014) Interferons: Success in anti-viral immunotherapy. Cytokine Growth Factor Rev 25:369\u2013376","journal-title":"Cytokine Growth Factor Rev"},{"key":"3138_CR9","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1099\/vir.0.18974-0","volume":"84","author":"G Buttinelli","year":"2003","unstructured":"Buttinelli G, Donati V, Fiore S et al (2003) Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J Gen Virol 84:1215\u20131221. https:\/\/doi.org\/10.1099\/vir.0.18974-0","journal-title":"J Gen Virol"},{"key":"3138_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/978-1-4419-7185-2_15","volume":"697","author":"C Thompson","year":"2011","unstructured":"Thompson C, Whitley R (2011) Neonatal herpes simplex virus infections: where are we now? Adv Exp Med Biol 697:221\u2013230. https:\/\/doi.org\/10.1007\/978-1-4419-7185-2_15","journal-title":"Adv Exp Med Biol"},{"key":"3138_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0002-9343(82)90055-9","volume":"73","author":"GB Elion","year":"1982","unstructured":"Elion GB (1982) Mechanism of action and selectivity of acyclovir. Am J Med 73:7\u201313. https:\/\/doi.org\/10.1016\/0002-9343(82)90055-9","journal-title":"Am J Med"},{"key":"3138_CR12","doi-asserted-by":"publisher","first-page":"7310","DOI":"10.1128\/jvi.00355-12","volume":"86","author":"S Duraffour","year":"2012","unstructured":"Duraffour S, Andrei G, Topalis D et al (2012) Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus. J Virol 86:7310\u20137325. https:\/\/doi.org\/10.1128\/jvi.00355-12","journal-title":"J Virol"},{"key":"3138_CR13","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/cid\/cis1035","volume":"56","author":"AK Le Page","year":"2013","unstructured":"Le Page AK, Jager MM, Iwasenko JM et al (2013) Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients. Clin Infect Dis 56:1018\u20131029. https:\/\/doi.org\/10.1093\/cid\/cis1035","journal-title":"Clin Infect Dis"},{"key":"3138_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1089\/aid.2012.0283","volume":"29","author":"V Musiime","year":"2013","unstructured":"Musiime V, Kaudha E, Kayiwa J et al (2013) Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected ugandan children. AIDS Res Hum Retroviruses 29:449\u2013455. https:\/\/doi.org\/10.1089\/aid.2012.0283","journal-title":"AIDS Res Hum Retroviruses"},{"key":"3138_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1592\/phco.31.4.357","volume":"4","author":"P Deming","year":"2011","unstructured":"Deming P, McNicholl IR (2011) Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances\u2014insights from the society of infectious diseases pharmacists. Pharmacotherapy 4:357\u2013368. https:\/\/doi.org\/10.1592\/phco.31.4.357","journal-title":"Pharmacotherapy"},{"key":"3138_CR16","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/resp.13114","volume":"22","author":"DSC Hui","year":"2017","unstructured":"Hui DSC, Lee N, Chan PKS (2017) A clinical approach to the threat of emerging influenza viruses in the Asia\u2013Pacific region. Respirology 22:1300\u20131312. https:\/\/doi.org\/10.1111\/resp.13114","journal-title":"Respirology"},{"key":"3138_CR17","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.3201\/eid2313.170727","volume":"23","author":"BJ Marston","year":"2017","unstructured":"Marston BJ, Dokubo EK, van Steelandt A et al (2017) Ebola response impact on public health programs, West Africa, 2014\u20132017. Emerg Infect Dis 23:S25\u2013S32. https:\/\/doi.org\/10.3201\/eid2313.170727","journal-title":"Emerg Infect Dis"},{"key":"3138_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10198-017-0940-4","volume":"19","author":"AWM Suijkerbuijk","year":"2017","unstructured":"Suijkerbuijk AWM, Swaan CM, Mangen M-JJ et al (2017) Ebola in the Netherlands, 2014\u20132015: costs of preparedness and response. Eur J Heal Econ 19:1\u20139. https:\/\/doi.org\/10.1007\/s10198-017-0940-4","journal-title":"Eur J Heal Econ"},{"key":"3138_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-018-5039-z","volume":"18","author":"Souza WV De","year":"2018","unstructured":"De Souza WV, De Albuquerque MDFPM, Vazquez E et al (2018) Microcephaly epidemic related to the Zika virus and living conditions in Recife, Northeast Brazil. BMC Public Health 18:1\u20137. https:\/\/doi.org\/10.1186\/s12889-018-5039-z","journal-title":"BMC Public Health"},{"key":"3138_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijerph15010096","volume":"15","author":"R Lowe","year":"2018","unstructured":"Lowe R, Barcellos C, Brasil P et al (2018) The zika virus epidemic in brazil: from discovery to future implications. Int J Environ Res Public Health 15:1\u201318. https:\/\/doi.org\/10.3390\/ijerph15010096","journal-title":"Int J Environ Res Public Health"},{"key":"3138_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2015.00517","volume":"6","author":"ZhuJ Da","year":"2015","unstructured":"Da ZhuJ, Meng W, Wang XJ, Wang HCR (2015) Broad-spectrum antiviral agents. Front Microbiol 6:1\u201315. https:\/\/doi.org\/10.3389\/fmicb.2015.00517","journal-title":"Front Microbiol"},{"key":"3138_CR22","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1128\/aac.01448-09","volume":"54","author":"G Wang","year":"2010","unstructured":"Wang G, Watson KM, Peterkofsky A, Buckheit RW (2010) Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. Antimicrob Agents Chemother 54:1343\u20131346. https:\/\/doi.org\/10.1128\/aac.01448-09","journal-title":"Antimicrob Agents Chemother"},{"key":"3138_CR23","doi-asserted-by":"publisher","first-page":"870","DOI":"10.6026\/97320630008870","volume":"8","author":"T Jesus","year":"2012","unstructured":"Jesus T, Rogelio L, Abraham C et al (2012) Prediction of antiviral peptides derived from viral fusion proteins potentially active against herpes simplex and influenza A viruses. Bioinformation 8:870\u2013874. https:\/\/doi.org\/10.6026\/97320630008870","journal-title":"Bioinformation"},{"key":"3138_CR24","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1128\/jvi.03050-13","volume":"88","author":"HA Elshabrawy","year":"2014","unstructured":"Elshabrawy HA, Fan J, Haddad CS et al (2014) Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and ebola, hendra, and nipah viruses by using a novel high-throughput screening assay. J Virol 88:4353\u20134365. https:\/\/doi.org\/10.1128\/jvi.03050-13","journal-title":"J Virol"},{"key":"3138_CR25","first-page":"581","volume":"3","author":"FO Martins","year":"2009","unstructured":"Martins FO, da Rocha Gomes MM, Pereira Nogueira FL et al (2009) In vitro inhibitory effect of Urera baccifera (L.) Gaudich. extracts against herpes simplex. African J Pharm Pharmacol 3:581\u2013584","journal-title":"African J Pharm Pharmacol"},{"key":"3138_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6882-13-139","volume":"13","author":"A Cantatore","year":"2013","unstructured":"Cantatore A, Randall SD, Traum D, Adams SD (2013) Effect of black tea extract on herpes simplex virus-1 infection of cultured cells. BMC Compl Altern Med 13:1\u201310. https:\/\/doi.org\/10.1186\/1472-6882-13-139","journal-title":"BMC Compl Altern Med"},{"key":"3138_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2180-14-140","volume":"14","author":"HA Rothan","year":"2014","unstructured":"Rothan HA, Bahrani H, Rahman NA, Yusof R (2014) Identification of natural antimicrobial agents to treat dengue infection: in vitro analysis of latarcin peptide activity against dengue virus. BMC Microbiol 14:1\u201310. https:\/\/doi.org\/10.1186\/1471-2180-14-140","journal-title":"BMC Microbiol"},{"key":"3138_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/251482","volume":"2012","author":"HA Rothan","year":"2012","unstructured":"Rothan HA, Abdulrahman AY, Sasikumer PG et al (2012) Protegrin-1 inhibits dengue NS2B-NS3 serine protease and viral replication in MK2 cells. J Biomed Biotechnol 2012:1\u20136. https:\/\/doi.org\/10.1155\/2012\/251482","journal-title":"J Biomed Biotechnol"},{"key":"3138_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-12-314","volume":"12","author":"HA Rothan","year":"2012","unstructured":"Rothan HA, Han HC, Ramasamy TS et al (2012) Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1. BMC Infect Dis 12:1\u20139. https:\/\/doi.org\/10.1186\/1471-2334-12-314","journal-title":"BMC Infect Dis"},{"key":"3138_CR30","doi-asserted-by":"publisher","first-page":"12295","DOI":"10.1074\/jbc.m113.450973","volume":"288","author":"A Hakim","year":"2013","unstructured":"Hakim A, Nguyen JB, Basu K et al (2013) Crystal structure of an insect antifreeze protein and its implications for ice binding. J Biol Chem 288:12295\u201312304. https:\/\/doi.org\/10.1074\/jbc.m113.450973","journal-title":"J Biol Chem"},{"key":"3138_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.virusres.2012.10.032","volume":"171","author":"HZA Ishag","year":"2013","unstructured":"Ishag HZA, Li C, Huang L et al (2013) Inhibition of Japanese encephalitis virus infection in vitro and in vivo by pokeweed antiviral protein. Virus Res 171:89\u201396. https:\/\/doi.org\/10.1016\/j.virusres.2012.10.032","journal-title":"Virus Res"},{"key":"3138_CR32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.antiviral.2017.02.009","volume":"141","author":"L Chen","year":"2017","unstructured":"Chen L, Liu Y, Wang S et al (2017) Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses. Antiviral Res 141:140\u2013149. https:\/\/doi.org\/10.1016\/j.antiviral.2017.02.009","journal-title":"Antiviral Res"},{"key":"3138_CR33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.virol.2004.02.029","volume":"323","author":"VG Chinchar","year":"2004","unstructured":"Chinchar VG, Bryan L, Silphadaung U et al (2004) Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides. Virology 323:268\u2013275. https:\/\/doi.org\/10.1016\/j.virol.2004.02.029","journal-title":"Virology"},{"key":"3138_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.antiviral.2007.06.006","volume":"76","author":"A Falco","year":"2007","unstructured":"Falco A, Mas V, Tafalla C et al (2007) Dual antiviral activity of human alpha-defensin-1 against viral haemorrhagic septicaemia rhabdovirus (VHSV): inactivation of virus particles and induction of a type I interferon-related response. Antiviral Res 76:111\u2013123. https:\/\/doi.org\/10.1016\/j.antiviral.2007.06.006","journal-title":"Antiviral Res"},{"key":"3138_CR35","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1365-2230.2012.04305.x","volume":"37","author":"LR Crack","year":"2012","unstructured":"Crack LR, Jones L, Malavige GN et al (2012) Human antimicrobial peptides LL-37 and human \u03b2-defensin-2 reduce viral replication in keratinocytes infected with varicella zoster virus. Clin Exp Dermatol 37:534\u2013543. https:\/\/doi.org\/10.1111\/j.1365-2230.2012.04305.x","journal-title":"Clin Exp Dermatol"},{"key":"3138_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-422x-9-6","volume":"6","author":"SE Altmann","year":"2012","unstructured":"Altmann SE, Brandt CR, Jahrling PB, Blaney JE (2012) Antiviral activity of the EB peptide against zoonotic poxviruses. Virol J 6:1\u20136. https:\/\/doi.org\/10.1186\/1743-422x-9-6","journal-title":"Virol J"},{"key":"3138_CR37","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1099\/vir.0.80051-0","volume":"85","author":"K Okazaki","year":"2004","unstructured":"Okazaki K, Kida H (2004) A synthetic peptide from a heptad repeat region of herpesvirus glycoprotein B inhibits virus replication. J Gen Virol 85:2131\u20132137. https:\/\/doi.org\/10.1099\/vir.0.80051-0","journal-title":"J Gen Virol"},{"key":"3138_CR38","doi-asserted-by":"publisher","first-page":"25406","DOI":"10.1074\/jbc.m110.201103","volume":"286","author":"V Tiwari","year":"2011","unstructured":"Tiwari V, Liu J, Valyi-Nagy T, Shukla D (2011) Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo. J Biol Chem 286:25406\u201325415. https:\/\/doi.org\/10.1074\/jbc.m110.201103","journal-title":"J Biol Chem"},{"key":"3138_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0045012","volume":"7","author":"C Mooney","year":"2012","unstructured":"Mooney C, Haslam NJ, Pollastri G, Shields DC (2012) Towards the improved discovery and design of functional peptides: common features of diverse classes permit generalized prediction of bioactivity. PLoS One 7:1\u201312. https:\/\/doi.org\/10.1371\/journal.pone.0045012","journal-title":"PLoS One"},{"key":"3138_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pcbi.1003212","volume":"9","author":"G Maccari","year":"2013","unstructured":"Maccari G, Di Luca M, Nifos\u00ed R et al (2013) Antimicrobial peptides design by evolutionary multiobjective optimization. PLoS Comput Biol 9:1\u201312. https:\/\/doi.org\/10.1371\/journal.pcbi.1003212","journal-title":"PLoS Comput Biol"},{"key":"3138_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-15-282","volume":"15","author":"A Sharma","year":"2014","unstructured":"Sharma A, Singla D, Rashid M, Raghava GPS (2014) Designing of peptides with desired half-life in intestine-like environment. BMC Bioinf 15:1\u20138. https:\/\/doi.org\/10.1186\/1471-2105-15-282","journal-title":"BMC Bioinf"},{"key":"3138_CR42","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/nar\/gkt1191","volume":"42","author":"A Qureshi","year":"2014","unstructured":"Qureshi A, Thakur N, Tandon H, Kumar M (2014) AVPdb: a database of experimentally validated antiviral peptides targeting medically important viruses. Nucleic Acids Res 42:1147\u20131153. https:\/\/doi.org\/10.1093\/nar\/gkt1191","journal-title":"Nucleic Acids Res"},{"key":"3138_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2013.00321","volume":"4","author":"KCL Mulder","year":"2013","unstructured":"Mulder KCL, Lima LA, Miranda VJ et al (2013) Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides. Front Microbiol 4:1\u201323. https:\/\/doi.org\/10.3389\/fmicb.2013.00321","journal-title":"Front Microbiol"},{"key":"3138_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2217\/fmb.13.135","volume":"9","author":"PG Barlow","year":"2014","unstructured":"Barlow PG, Findlay EG, Currie SM, Davidson DJ (2014) Antiviral potential of cathelicidins. Future Microbiol 9:55\u201373. https:\/\/doi.org\/10.2217\/fmb.13.135","journal-title":"Future Microbiol"},{"key":"3138_CR45","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40259-013-0039-0","volume":"27","author":"E Gwyer Findlay","year":"2013","unstructured":"Gwyer Findlay E, Currie SM, Davidson DJ (2013) Cationic host defence peptides: potential as antiviral therapeutics. BioDrugs 27:479\u2013493. https:\/\/doi.org\/10.1007\/s40259-013-0039-0","journal-title":"BioDrugs"},{"key":"3138_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/psc.2489","volume":"19","author":"S Galdiero","year":"2013","unstructured":"Galdiero S, Falanga A, Tarallo R et al (2013) Peptide inhibitors against herpes simplex virus infections. J Pept Sci 19:148\u2013158. https:\/\/doi.org\/10.1002\/psc.2489","journal-title":"J Pept Sci"},{"key":"3138_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0054908","volume":"8","author":"A Qureshi","year":"2013","unstructured":"Qureshi A, Thakur N, Kumar M (2013) HIPdb: a database of experimentally validated hiv inhibiting peptides. PLoS One 8:1\u20135. https:\/\/doi.org\/10.1371\/journal.pone.0054908","journal-title":"PLoS One"},{"key":"3138_CR48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.micinf.2015.10.009","volume":"18","author":"W Zapata","year":"2016","unstructured":"Zapata W, Aguilar-Jim\u00e9nez W, Feng Z et al (2016) Identification of innate immune antiretroviral factors during in vivo and in vitro exposure to HIV-1. Microbes Infect 18:211\u2013219. https:\/\/doi.org\/10.1016\/j.micinf.2015.10.009","journal-title":"Microbes Infect"},{"key":"3138_CR49","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.0105-2896.2004.0124.x","volume":"198","author":"P Bulet","year":"2004","unstructured":"Bulet P, St\u00f6cklin R, Menin L (2004) Anti-microbial peptides: from invertebrates to vertebrates. Immunol Rev 198:169\u2013184","journal-title":"Immunol Rev"},{"key":"3138_CR50","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/j.bbamem.2014.04.015","volume":"1838","author":"H Badani","year":"2014","unstructured":"Badani H, Garry RF, Wimley WC (2014) Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity. Biochim Biophys Acta Biomembr 1838:2180\u20132197. https:\/\/doi.org\/10.1016\/j.bbamem.2014.04.015","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"3138_CR51","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3390\/molecules22112037","volume":"22","author":"C-K Wang","year":"2017","unstructured":"Wang C-K, Shih L-Y, Chang K (2017) Large-scale analysis of antimicrobial activities in relation to amphipathicity and charge reveals novel characterization of antimicrobial peptides. Molecules 22:2037. https:\/\/doi.org\/10.3390\/molecules22112037","journal-title":"Molecules"},{"key":"3138_CR52","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3390\/ph8040711","volume":"8","author":"JP Tam","year":"2015","unstructured":"Tam JP, Wang S, Wong KH, Tan WL (2015) Antimicrobial peptides from plants. Pharmaceuticals 8:711\u2013757. https:\/\/doi.org\/10.3390\/ph8040711","journal-title":"Pharmaceuticals"},{"key":"3138_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpls.2015.00855","volume":"6","author":"R Burman","year":"2015","unstructured":"Burman R, Yeshak MY, Larsson S et al (2015) Distribution of circular proteins in plants: large-scale mapping of cyclotides in the Violaceae. Front Plant Sci 6:1\u201313. https:\/\/doi.org\/10.3389\/fpls.2015.00855","journal-title":"Front Plant Sci"},{"key":"3138_CR54","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.1093\/jxb\/erw210","volume":"67","author":"J Weidmann","year":"2016","unstructured":"Weidmann J, Craik DJ (2016) Discovery, structure, function, and applications of cyclotides: circular proteins from plants. J Exp Bot 67:4801\u20134812. https:\/\/doi.org\/10.1093\/jxb\/erw210","journal-title":"J Exp Bot"},{"key":"3138_CR55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/bip.20886","volume":"90","author":"DC Ireland","year":"2008","unstructured":"Ireland DC, Wang CKL, Wilson JA et al (2008) Cyclotides as natural anti-HIV agents. Biopolym - Pept Sci Sect 90:51\u201360. https:\/\/doi.org\/10.1002\/bip.20886","journal-title":"Biopolym - Pept Sci Sect"},{"key":"3138_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1021\/np070393g","volume":"71","author":"CKL Wang","year":"2008","unstructured":"Wang CKL, Colgrave ML, Gustafson KR et al (2008) Anti-HIV cyclotides from the Chinese medicinal herb Viola yedoensis. J Nat Prod 71:47\u201352. https:\/\/doi.org\/10.1021\/np070393g","journal-title":"J Nat Prod"},{"key":"3138_CR57","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.drudis.2009.10.007","volume":"7","author":"ST Henriques","year":"2010","unstructured":"Henriques ST, Craik DJ (2010) Cyclotides as templates in drug design. Drug Discov Today 7:179\u2013194. https:\/\/doi.org\/10.1016\/j.drudis.2009.10.007","journal-title":"Drug Discov Today"},{"key":"3138_CR58","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.bmc.2009.12.026","volume":"18","author":"Y Gao","year":"2010","unstructured":"Gao Y, Cui T, Lam Y (2010) Synthesis and disulfide bond connectivity-activity studies of a kalata B1-inspired cyclopeptide against dengue NS2B-NS3 protease. Bioorganic Med Chem 18:1331\u20131336. https:\/\/doi.org\/10.1016\/j.bmc.2009.12.026","journal-title":"Bioorganic Med Chem"},{"key":"3138_CR59","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.2174\/1381612821666151002113426","volume":"21","author":"M Sencanski","year":"2015","unstructured":"Sencanski M, Radosevic D, Perovic V et al (2015) Natural products as promising therapeutics for treatment of influenza disease. Curr Pharm Des 21:5573\u20135588. https:\/\/doi.org\/10.2174\/1381612821666151002113426","journal-title":"Curr Pharm Des"},{"key":"3138_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1074\/jbc.m111.253393","volume":"286","author":"ST Henriques","year":"2011","unstructured":"Henriques ST, Huang YH, Rosengren KJ et al (2011) Decoding the membrane activity of the cyclotide kalata B1: the importance of phosphatidylethanolamine phospholipids and lipid organization on hemolytic and anti-HIV activities. J Biol Chem 286:1\u201324. https:\/\/doi.org\/10.1074\/jbc.m111.253393","journal-title":"J Biol Chem"},{"key":"3138_CR61","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.virusres.2009.04.007","volume":"143","author":"AA Waheed","year":"2009","unstructured":"Waheed AA, Freed EO (2009) Lipids and membrane microdomains in HIV-1 replication. Virus Res 143:162\u2013176. https:\/\/doi.org\/10.1016\/j.virusres.2009.04.007","journal-title":"Virus Res"},{"key":"3138_CR62","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.febslet.2004.08.007","volume":"574","author":"NL Daly","year":"2004","unstructured":"Daly NL, Gustafson KR, Craik DJ (2004) The role of the cyclic peptide backbone in the anti-HIV activity of the cyclotide kalata B1. FEBS Lett 574:69\u201372. https:\/\/doi.org\/10.1016\/j.febslet.2004.08.007","journal-title":"FEBS Lett"},{"key":"3138_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-03745-2","volume":"7","author":"W Nawae","year":"2017","unstructured":"Nawae W, Hannongbua S, Ruengjitchatchawalya M (2017) Molecular dynamics exploration of poration and leaking caused by Kalata B1 in HIV-infected cell membrane compared to host and HIV membranes. Sci Rep 7:1\u201313. https:\/\/doi.org\/10.1038\/s41598-017-03745-2","journal-title":"Sci Rep"},{"key":"3138_CR64","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cbpa.2017.01.018","volume":"38","author":"DJ Craik","year":"2017","unstructured":"Craik DJ, Du J (2017) Cyclotides as drug design scaffolds. Curr Opin Chem Biol 38:8\u201316. https:\/\/doi.org\/10.1016\/j.cbpa.2017.01.018","journal-title":"Curr Opin Chem Biol"},{"key":"3138_CR65","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1139\/o05-037","volume":"83","author":"PH Ngai","year":"2005","unstructured":"Ngai PH, Ng TB (2005) Phaseococcin, an antifungal protein with antiproliferative and anti-HIV-1 reverse transcriptase activities from small scarlet runner beans. Biochem Cell Biol 83:212\u2013220. https:\/\/doi.org\/10.1139\/o05-037","journal-title":"Biochem Cell Biol"},{"key":"3138_CR66","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.peptides.2005.01.003","volume":"26","author":"HW Jack","year":"2005","unstructured":"Jack HW, Tzi BN (2005) Sesquin, a potent defensin-like antimicrobial peptide from ground beans with inhibitory activities toward tumor cells and HIV-1 reverse transcriptase. Peptides 26:1120\u20131126. https:\/\/doi.org\/10.1016\/j.peptides.2005.01.003","journal-title":"Peptides"},{"key":"3138_CR67","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.phymed.2007.07.059","volume":"15","author":"I Camargo Filho","year":"2008","unstructured":"Camargo Filho I, Cortez DAG, Ueda-Nakamura T et al (2008) Antiviral activity and mode of action of a peptide isolated from Sorghum bicolor. Phytomedicine 15:202\u2013208. https:\/\/doi.org\/10.1016\/j.phymed.2007.07.059","journal-title":"Phytomedicine"},{"key":"3138_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/102129","volume":"2015","author":"CE Salas","year":"2015","unstructured":"Salas CE, Badillo-Corona JA, Ram\u00edrez-Sotelo G, Oliver-Salvador C (2015) Biologically active and antimicrobial peptides from plants. Biomed Res Int 2015:1\u201311. https:\/\/doi.org\/10.1155\/2015\/102129","journal-title":"Biomed Res Int"},{"key":"3138_CR69","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/psc.1219","volume":"16","author":"M Kuczer","year":"2010","unstructured":"Kuczer M, Dziubasik K, Midak-Siewirska A et al (2010) Studies of insect peptides alloferon, Any-GS and their analogues. Synthesis and antiherpes activity. J Pept Sci 16:186\u2013189. https:\/\/doi.org\/10.1002\/psc.1219","journal-title":"J Pept Sci"},{"key":"3138_CR70","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1432-1033.1980.tb05991.x","volume":"106","author":"D Hultmark","year":"2005","unstructured":"Hultmark D, Steiner H, Rasmuson T, Boman HG (2005) Insect immunity. Purification and properties of three inducible bactericidal proteins from hemolymph of immunized pupae of Hyalophora cecropia. Eur J Biochem 106:7\u201316. https:\/\/doi.org\/10.1111\/j.1432-1033.1980.tb05991.x","journal-title":"Eur J Biochem"},{"key":"3138_CR71","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1099\/0022-1317-79-4-731","volume":"79","author":"M Wachinger","year":"1998","unstructured":"Wachinger M, Kleinschmidt A, Winder D et al (1998) Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression. J Gen Virol 79:731\u2013740. https:\/\/doi.org\/10.1099\/0022-1317-79-4-731","journal-title":"J Gen Virol"},{"key":"3138_CR72","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ijantimicag.2003.07.022","volume":"23","author":"VC Albiol Matanic","year":"2004","unstructured":"Albiol Matanic VC, Castilla V (2004) Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. Int J Antimicrob Agents 23:382\u2013389. https:\/\/doi.org\/10.1016\/j.ijantimicag.2003.07.022","journal-title":"Int J Antimicrob Agents"},{"key":"3138_CR73","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0014-5793(92)80780-k","volume":"309","author":"M Wachinger","year":"1992","unstructured":"Wachinger M, Saermark T, Erfle V (1992) Influence of amphipathic peptides on the HIV-1 production in persistently infected T lymphoma cells. FEBS Lett 309:235\u2013241. https:\/\/doi.org\/10.1016\/0014-5793(92)80780-k","journal-title":"FEBS Lett"},{"key":"3138_CR74","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3851\/imp2346","volume":"18","author":"JL Hood","year":"2013","unstructured":"Hood JL, Jallouk AP, Campbell N et al (2013) Cytolytic nanoparticles attenuate HIV-1 infectivity. Antivir Ther 18:95\u2013103. https:\/\/doi.org\/10.3851\/imp2346","journal-title":"Antivir Ther"},{"key":"3138_CR75","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.peptides.2013.07.014","volume":"48","author":"CJ Sample","year":"2013","unstructured":"Sample CJ, Hudak KE, Barefoot BE et al (2013) A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses. Peptides 48:96\u2013105. https:\/\/doi.org\/10.1016\/j.peptides.2013.07.014","journal-title":"Peptides"},{"key":"3138_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-015-0276-6","volume":"12","author":"AM El-Bitar","year":"2015","unstructured":"El-Bitar AM, Sarhan MM, Aoki C et al (2015) Virocidal activity of Egyptian scorpion venoms against hepatitis C virus Hepatitis viruses. Virol J 12:1\u20139. https:\/\/doi.org\/10.1186\/s12985-015-0276-6","journal-title":"Virol J"},{"key":"3138_CR77","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.peptides.2010.10.008","volume":"32","author":"R Yan","year":"2011","unstructured":"Yan R, Zhao Z, He Y et al (2011) A new natural \u03b1-helical peptide from the venom of the scorpion Heterometrus petersii kills HCV. Peptides 32:11\u201319. https:\/\/doi.org\/10.1016\/j.peptides.2010.10.008","journal-title":"Peptides"},{"key":"3138_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2013.11.013","volume":"102","author":"W Hong","year":"2014","unstructured":"Hong W, Li T, Song Y et al (2014) Inhibitory activity and mechanism of two scorpion venom peptides against herpes simplex virus type 1. Antiviral Res 102:1\u201310. https:\/\/doi.org\/10.1016\/j.antiviral.2013.11.013","journal-title":"Antiviral Res"},{"key":"3138_CR79","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.peptides.2011.05.015","volume":"32","author":"Q Li","year":"2011","unstructured":"Li Q, Zhao Z, Zhou D et al (2011) Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. Peptides 32:1518\u20131525. https:\/\/doi.org\/10.1016\/j.peptides.2011.05.015","journal-title":"Peptides"},{"key":"3138_CR80","doi-asserted-by":"publisher","first-page":"30181","DOI":"10.1074\/jbc.m112.370312","volume":"287","author":"Z Zhao","year":"2012","unstructured":"Zhao Z, Hong W, Zeng Z et al (2012) Mucroporin-M1 inhibits hepatitis B virus replication by activating the mitogen-activated protein kinase (MAPK) pathway and down-regulating HNF4\u03b1 in vitro and in vivo. J Biol Chem 287:30181\u201330190. https:\/\/doi.org\/10.1074\/jbc.m112.370312","journal-title":"J Biol Chem"},{"key":"3138_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0034947","volume":"7","author":"Y Chen","year":"2012","unstructured":"Chen Y, Cao L, Zhong M et al (2012) Anti-HIV-1 activity of a new scorpion venom peptide derivative Kn2-7. PLoS One 7:1\u20139. https:\/\/doi.org\/10.1371\/journal.pone.0034947","journal-title":"PLoS One"},{"key":"3138_CR82","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7150\/thno.21425","volume":"8","author":"Z Zeng","year":"2018","unstructured":"Zeng Z, Zhang R, Hong W et al (2018) Histidine-rich modification of a scorpion-derived peptide improves bioavailability and inhibitory activity against HSV-1. Theranostics 8:199\u2013211. https:\/\/doi.org\/10.7150\/thno.21425","journal-title":"Theranostics"},{"key":"3138_CR83","doi-asserted-by":"publisher","first-page":"12628","DOI":"10.1073\/pnas.192301899","volume":"99","author":"S Chernysh","year":"2002","unstructured":"Chernysh S, Kim SI, Bekker G et al (2002) Antiviral and antitumor peptides from insects. Proc Natl Acad Sci 99:12628\u201312632. https:\/\/doi.org\/10.1073\/pnas.192301899","journal-title":"Proc Natl Acad Sci"},{"key":"3138_CR84","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/psc.1388","volume":"17","author":"M Kuczer","year":"2011","unstructured":"Kuczer M, Midak-Siewirska A, Zahorska R et al (2011) Further studies on the antiviral activity of alloferon and its analogues. J Pept Sci 17:715\u2013719. https:\/\/doi.org\/10.1002\/psc.1388","journal-title":"J Pept Sci"},{"key":"3138_CR85","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/cbdd.12020","volume":"81","author":"M Kuczer","year":"2013","unstructured":"Kuczer M, Majewska A, Zahorska R (2013) New alloferon analogues: synthesis and antiviral properties. Chem Biol Drug Des 81:302\u2013309. https:\/\/doi.org\/10.1111\/cbdd.12020","journal-title":"Chem Biol Drug Des"},{"key":"3138_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/aac.02367-17","volume":"62","author":"ME Marcocci","year":"2018","unstructured":"Marcocci ME, Amatore D, Villa S et al (2018) The amphibian antimicrobial peptide temporin b inhibits in vitro herpes simplex virus 1 infection. Antimicrob Agents Chemother 62:1\u201313. https:\/\/doi.org\/10.1128\/aac.02367-17","journal-title":"Antimicrob Agents Chemother"},{"key":"3138_CR87","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semcdb.2018.03.001","volume":"88","author":"JR Shartouny","year":"2018","unstructured":"Shartouny JR, Jacob J (2018) Mining the tree of life: host defense peptides as antiviral therapeutics. Semin Cell Dev Biol 88:147\u2013155. https:\/\/doi.org\/10.1016\/j.semcdb.2018.03.001","journal-title":"Semin Cell Dev Biol"},{"key":"3138_CR88","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0924-8579(99)00094-1","volume":"13","author":"M Egal","year":"1999","unstructured":"Egal M, Conrad M, MacDonald DL et al (1999) Antiviral effects of synthetic membrane-active peptides on herpes simplex virus, type 1. Int J Antimicrob Agents 13:57\u201360","journal-title":"Int J Antimicrob Agents"},{"key":"3138_CR89","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.peptides.2010.07.028","volume":"31","author":"RE Dean","year":"2010","unstructured":"Dean RE, O\u2019Brien LM, Thwaite JE et al (2010) A carpet-based mechanism for direct antimicrobial peptide activity against vaccinia virus membranes. Peptides 31:1966\u20131972. https:\/\/doi.org\/10.1016\/j.peptides.2010.07.028","journal-title":"Peptides"},{"key":"3138_CR90","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jmv.2134","volume":"66","author":"A Belaid","year":"2002","unstructured":"Belaid A, Aouni M, Khelifa R et al (2002) In vitro antiviral activity of dermaseptins against herpes simplex virus type 1. J Med Virol 66:229\u2013234. https:\/\/doi.org\/10.1002\/jmv.2134","journal-title":"J Med Virol"},{"key":"3138_CR91","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.virol.2005.02.002","volume":"334","author":"C Lorin","year":"2005","unstructured":"Lorin C, Saidi H, Belaid A et al (2005) The antimicrobial peptide Dermaseptin S4 inhibits HIV-1 infectivity in vitro. Virology 334:264\u2013275. https:\/\/doi.org\/10.1016\/j.virol.2005.02.002","journal-title":"Virology"},{"key":"3138_CR92","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/jmv.23450","volume":"85","author":"I Bergaoui","year":"2013","unstructured":"Bergaoui I, Zairi A, Tangy F et al (2013) In vitro antiviral activity of dermaseptin S4 and derivatives from amphibian skin against herpes simplex virus type 2. J Med Virol 85:272\u2013281. https:\/\/doi.org\/10.1002\/jmv.23450","journal-title":"J Med Virol"},{"key":"3138_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vaccine.2018.01.066","volume":"2018","author":"MB Mechlia","year":"2018","unstructured":"Mechlia MB, Belaid A, Castel G et al (2018) Dermaseptins as potential antirabies compounds. Vaccine 2018:1\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.066","journal-title":"Vaccine"},{"key":"3138_CR94","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.virol.2017.11.009","volume":"514","author":"JMC Monteiro","year":"2018","unstructured":"Monteiro JMC, Oliveira MD, Dias RS et al (2018) The antimicrobial peptide HS-1 inhibits dengue virus infection. Virology 514:79\u201387. https:\/\/doi.org\/10.1016\/j.virol.2017.11.009","journal-title":"Virology"},{"key":"3138_CR95","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.immuni.2017.03.018","volume":"46","author":"DJ Holthausen","year":"2017","unstructured":"Holthausen DJ, Lee SH, Kumar VT et al (2017) An amphibian host defense peptide is virucidal for human H1 hemagglutinin-bearing influenza viruses. Immunity 46:587\u2013595. https:\/\/doi.org\/10.1016\/j.immuni.2017.03.018","journal-title":"Immunity"},{"key":"3138_CR96","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s100960050457","volume":"19","author":"B Yasin","year":"2000","unstructured":"Yasin B, Pang M, Turner JS et al (2000) Evaluation of the inactivation of infectious herpes simplex virus by host-defense peptides. Eur J Clin Microbiol Infect Dis 19:187\u2013194. https:\/\/doi.org\/10.1007\/s100960050457","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"3138_CR97","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1590\/s0074-02762007005000028","volume":"102","author":"MC Carriel-Gomes","year":"2007","unstructured":"Carriel-Gomes MC, Kratz JM, Barracco MA et al (2007) In vitro antiviral activity of antimicrobial peptides against herpes simplex virus 1, adenovirus, and rotavirus. Mem Inst Oswaldo Cruz 102:469\u2013472. https:\/\/doi.org\/10.1590\/s0074-02762007005000028","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"3138_CR98","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1021\/np100613p","volume":"74","author":"Z Lu","year":"2011","unstructured":"Lu Z, Van Wagoner RM, Harper MK et al (2011) Mirabamides E\u2013H, HIV-inhibitory depsipeptides from the sponge Stelletta clavosa. J Nat Prod 74:185\u2013193. https:\/\/doi.org\/10.1021\/np100613p","journal-title":"J Nat Prod"},{"key":"3138_CR99","doi-asserted-by":"publisher","first-page":"e47047","DOI":"10.1371\/journal.pone.0047047","volume":"7","author":"L Migliolo","year":"2012","unstructured":"Migliolo L, Silva ON, Silva PA et al (2012) Structural and functional characterization of a multifunctional alanine-rich peptide analogue from pleuronectes americanus. PLoS One 7:e47047. https:\/\/doi.org\/10.1371\/journal.pone.0047047","journal-title":"PLoS One"},{"key":"3138_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bip.22871","volume":"108","author":"LCP Vilas Boas","year":"2017","unstructured":"Vilas Boas LCP, de Lima LMP, Migliolo L et al (2017) Linear antimicrobial peptides with activity against herpes simplex virus 1 and Aichi virus. Biopolymers 108:1\u201320. https:\/\/doi.org\/10.1002\/bip.22871","journal-title":"Biopolymers"},{"key":"3138_CR101","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev-virology-101416-041734","volume":"4","author":"MK Holly","year":"2017","unstructured":"Holly MK, Diaz K, Smith JG (2017) Defensins in Viral Infection and Pathogenesis. Annu Rev Virol 4:369\u2013391. https:\/\/doi.org\/10.1146\/annurev-virology-101416-041734","journal-title":"Annu Rev Virol"},{"key":"3138_CR102","doi-asserted-by":"publisher","first-page":"515","DOI":"10.4049\/jimmunol.173.1.515","volume":"173","author":"W Wang","year":"2004","unstructured":"Wang W, Owen SM, Rudolph DL et al (2004) Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol 173:515\u2013520. https:\/\/doi.org\/10.4049\/jimmunol.173.1.515","journal-title":"J Immunol"},{"key":"3138_CR103","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.febslet.2004.11.062","volume":"579","author":"Z Wu","year":"2005","unstructured":"Wu Z, Cocchi F, Gentles D et al (2005) Human neutrophil \u03b1-defensin 4 inhibits HIV-1 infection in vitro. FEBS Lett 579:162\u2013166. https:\/\/doi.org\/10.1016\/j.febslet.2004.11.062","journal-title":"FEBS Lett"},{"key":"3138_CR104","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1086\/521027","volume":"196","author":"M Salvatore","year":"2007","unstructured":"Salvatore M, Garc\u00eda-Sastre A, Ruchala P et al (2007) \u03b1-defensin inhibits influenza virus replication by cell-mediated mechanism(s). J Infect Dis 196:835\u2013843. https:\/\/doi.org\/10.1086\/521027","journal-title":"J Infect Dis"},{"key":"3138_CR105","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/j.1468-3083.2008.02675.x","volume":"22","author":"U Meyer-Hoffert","year":"2008","unstructured":"Meyer-Hoffert U, Schwarz T, Schr\u00f6der J-M, Gl\u00e4ser R (2008) Expression of human beta-defensin-2 and -3 in verrucae vulgares and condylomata acuminata. J Eur Acad Dermatol Venereol 22:1050\u20131054. https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02675.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3138_CR106","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jaci.2007.01.044","volume":"119","author":"MD Howell","year":"2007","unstructured":"Howell MD, Streib JE, Leung DYM (2007) Antiviral activity of human beta-defensin 3 against vaccinia virus. J Allergy Clin Immunol 119:1022\u20131025. https:\/\/doi.org\/10.1016\/j.jaci.2007.01.044","journal-title":"J Allergy Clin Immunol"},{"key":"3138_CR107","doi-asserted-by":"publisher","first-page":"F39","DOI":"10.1097\/01.aids.0000096878.73209.4f","volume":"17","author":"ME Qui\u00f1ones-Mateu","year":"2003","unstructured":"Qui\u00f1ones-Mateu ME, Lederman MM, Feng Z et al (2003) Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 17:F39\u2013F48. https:\/\/doi.org\/10.1097\/01.aids.0000096878.73209.4f","journal-title":"AIDS"},{"key":"3138_CR108","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood.v97.12.3951","volume":"97","author":"OE S\u00f8rensen","year":"2001","unstructured":"S\u00f8rensen OE, Follin P, Johnsen AH et al (2001) Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97:3951\u20133959. https:\/\/doi.org\/10.1182\/blood.v97.12.3951","journal-title":"Blood"},{"key":"3138_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0025333","volume":"6","author":"PG Barlow","year":"2011","unstructured":"Barlow PG, Svoboda P, Mackellar A et al (2011) Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One 6:1\u20139. https:\/\/doi.org\/10.1371\/journal.pone.0025333","journal-title":"PLoS One"},{"key":"3138_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0124706","volume":"10","author":"S Tripathi","year":"2015","unstructured":"Tripathi S, Wang G, White M et al (2015) Antiviral activity of the human cathelicidin, LL-37, and derived peptides on seasonal and pandemic influenza A viruses. PLoS One 10:1\u201317. https:\/\/doi.org\/10.1371\/journal.pone.0124706","journal-title":"PLoS One"},{"key":"3138_CR111","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/hepr.12627","volume":"46","author":"T Matsumura","year":"2016","unstructured":"Matsumura T, Sugiyama N, Murayama A et al (2016) Antimicrobial peptide LL-37 attenuates infection of hepatitis C virus. Hepatol Res 46:924\u2013932. https:\/\/doi.org\/10.1111\/hepr.12627","journal-title":"Hepatol Res"},{"key":"3138_CR112","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.peptides.2017.04.002","volume":"92","author":"K Alagarasu","year":"2017","unstructured":"Alagarasu K, Patil PS, Shil P et al (2017) In-vitro effect of human cathelicidin antimicrobial peptide LL-37 on dengue virus type 2. Peptides 92:23\u201330. https:\/\/doi.org\/10.1016\/j.peptides.2017.04.002","journal-title":"Peptides"},{"key":"3138_CR113","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.antiviral.2019.02.002","volume":"164","author":"A Ahmed","year":"2019","unstructured":"Ahmed A, Siman-Tov G, Keck F et al (2019) Human cathelicidin peptide LL-37 as a therapeutic antiviral targeting Venezuelan equine encephalitis virus infections. Antiviral Res 164:61\u201369. https:\/\/doi.org\/10.1016\/j.antiviral.2019.02.002","journal-title":"Antiviral Res"},{"key":"3138_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.00722","volume":"9","author":"M He","year":"2018","unstructured":"He M, Zhang H, Li Y et al (2018) Cathelicidin-derived antimicrobial peptides inhibit Zika virus through direct inactivation and interferon pathway. Front Immunol 9:1\u201312. https:\/\/doi.org\/10.3389\/fimmu.2018.00722","journal-title":"Front Immunol"},{"key":"3138_CR115","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.peptides.2017.07.013","volume":"95","author":"FH Sousa","year":"2017","unstructured":"Sousa FH, Casanova V, Findlay F et al (2017) Cathelicidins display conserved direct antiviral activity towards rhinovirus. Peptides 95:76\u201383. https:\/\/doi.org\/10.1016\/j.peptides.2017.07.013","journal-title":"Peptides"},{"key":"3138_CR116","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/02713680590934111","volume":"30","author":"YJ Gordon","year":"2005","unstructured":"Gordon YJ, Huang LC, Romanowski EG et al (2005) Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res 30:385\u2013394. https:\/\/doi.org\/10.1080\/02713680590934111","journal-title":"Curr Eye Res"},{"key":"3138_CR117","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/s0166-3542(01)00195-4","volume":"52","author":"BWA Van der Strate","year":"2001","unstructured":"Van der Strate BWA, Beljaars L, Molema G et al (2001) Antiviral activities of lactoferrin. Antiviral Res 52:225\u2013239. https:\/\/doi.org\/10.1016\/s0166-3542(01)00195-4","journal-title":"Antiviral Res"},{"key":"3138_CR118","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00430-008-0100-7","volume":"198","author":"S Li","year":"2009","unstructured":"Li S, Zhou H, Huang G, Liu N (2009) Inhibition of HBV infection by bovine lactoferrin and iron-, zinc-saturated lactoferrin. Med Microbiol Immunol 198:19\u201325. https:\/\/doi.org\/10.1007\/s00430-008-0100-7","journal-title":"Med Microbiol Immunol"},{"key":"3138_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms18091957","volume":"18","author":"JM Chen","year":"2017","unstructured":"Chen JM, Fan YC, Lin JW et al (2017) Bovine lactoferrin inhibits dengue virus infectivity by interacting with heparan sulfate, low-density lipoprotein receptor, and DC-SIGN. Int J Mol Sci 18:1\u201313. https:\/\/doi.org\/10.3390\/ijms18091957","journal-title":"Int J Mol Sci"},{"key":"3138_CR120","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1099\/jgv.0.000849","volume":"98","author":"CAM Carvalho","year":"2017","unstructured":"Carvalho CAM, Casseb SMM, Gon\u00e7alves RB et al (2017) Bovine lactoferrin activity against Chikungunya and Zika viruses. J Gen Virol 98:1749\u20131754. https:\/\/doi.org\/10.1099\/jgv.0.000849","journal-title":"J Gen Virol"},{"key":"3138_CR121","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s0166-3542(01)00146-2","volume":"51","author":"JH Andersen","year":"2001","unstructured":"Andersen JH, Osbakk SA, Vorland LH et al (2001) Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Res 51:141\u2013149. https:\/\/doi.org\/10.1016\/s0166-3542(01)00146-2","journal-title":"Antiviral Res"},{"key":"3138_CR122","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.antiviral.2007.03.012","volume":"75","author":"N Mistry","year":"2007","unstructured":"Mistry N, Drobni P, N\u00e4slund J et al (2007) The anti-papillomavirus activity of human and bovine lactoferricin. Antiviral Res 75:258\u2013265. https:\/\/doi.org\/10.1016\/j.antiviral.2007.03.012","journal-title":"Antiviral Res"},{"key":"3138_CR123","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.biochi.2008.05.016","volume":"91","author":"AK Marr","year":"2009","unstructured":"Marr AK, Jenssen H, Moniri MR et al (2009) Bovine lactoferrin and lactoferricin interfere with intracellular trafficking of Herpes simplex virus-1. Biochimie 91:160\u2013164. https:\/\/doi.org\/10.1016\/j.biochi.2008.05.016","journal-title":"Biochimie"},{"key":"3138_CR124","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.antiviral.2012.01.003","volume":"93","author":"A Shestakov","year":"2012","unstructured":"Shestakov A, Jenssen H, Nordstr\u00f6m I, Eriksson K (2012) Lactoferricin but not lactoferrin inhibit herpes simplex virus type 2 infection in mice. Antiviral Res 93:340\u2013345. https:\/\/doi.org\/10.1016\/j.antiviral.2012.01.003","journal-title":"Antiviral Res"},{"key":"3138_CR125","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1007\/s12010-016-2059-y","volume":"179","author":"WY Wang","year":"2016","unstructured":"Wang WY, Wong JH, Ip DTM et al (2016) Bovine lactoferrampin, human lactoferricin, and lactoferrin 1-11 inhibit nuclear translocation of HIV integrase. Appl Biochem Biotechnol 179:1202\u20131212. https:\/\/doi.org\/10.1007\/s12010-016-2059-y","journal-title":"Appl Biochem Biotechnol"},{"key":"3138_CR126","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1128\/aac.00854-13","volume":"57","author":"EM Borst","year":"2013","unstructured":"Borst EM, St\u00e4ndker L, Wagner K et al (2013) A peptide inhibitor of cytomegalovirus infection from human hemofiltrate. Antimicrob Agents Chemother 57:4751\u20134760. https:\/\/doi.org\/10.1128\/aac.00854-13","journal-title":"Antimicrob Agents Chemother"},{"key":"3138_CR127","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000494354","volume":"61","author":"A Sala","year":"2018","unstructured":"Sala A, Ardizzoni A, Ciociola T et al (2018) Antiviral activity of synthetic peptides derived from physiological proteins. Intervirology 61:166\u2013173. https:\/\/doi.org\/10.1159\/000494354","journal-title":"Intervirology"},{"key":"3138_CR128","first-page":"377","volume-title":"Protein structure","author":"WF Porto","year":"2012","unstructured":"Porto WF, Silva ON, Franco OL (2012) Prediction and rational design of antimicrobial peptides. In: Faraggi E (ed) Protein structure. InTech, London, pp 377\u2013396"},{"key":"3138_CR129","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.compbiomed.2019.02.011","volume":"107","author":"JF Beltr\u00e1n Lissabet","year":"2019","unstructured":"Beltr\u00e1n Lissabet JF, Bel\u00e9n LH, Farias JG (2019) AntiVPP 1.0: a portable tool for prediction of antiviral peptides. Comput Biol Med 107:127\u2013130. https:\/\/doi.org\/10.1016\/j.compbiomed.2019.02.011","journal-title":"Comput Biol Med"},{"key":"3138_CR130","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1167\/iovs.12-10250","volume":"54","author":"GG Jose","year":"2013","unstructured":"Jose GG, Larsen IV, Gauger J et al (2013) A cationic peptide, TAT-Cd0, inhibits herpes simplex virus type 1 ocular infection in vivo. Investig Ophthalmol Vis Sci 54:1070\u20131079. https:\/\/doi.org\/10.1167\/iovs.12-10250","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"3138_CR131","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.antiviral.2018.04.018","volume":"155","author":"X Cui","year":"2018","unstructured":"Cui X, Wu Y, Fan D et al (2018) Peptides P4 and P7 derived from E protein inhibit entry of dengue virus serotype 2 via interacting with \u03b23 integrin. Antiviral Res 155:20\u201327. https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.018","journal-title":"Antiviral Res"},{"key":"3138_CR132","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.7150\/ijms.21875","volume":"14","author":"MF Chew","year":"2017","unstructured":"Chew MF, Poh KS, Poh CL (2017) Peptides as therapeutic agents for dengue virus. Int J Med Sci 14:1342\u20131359. https:\/\/doi.org\/10.7150\/ijms.21875","journal-title":"Int J Med Sci"},{"key":"3138_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-422x-2-49","volume":"2","author":"YM Hrobowski","year":"2005","unstructured":"Hrobowski YM, Garry RF, Michael SF (2005) Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J 2:1\u201310. https:\/\/doi.org\/10.1186\/1743-422x-2-49","journal-title":"Virol J"},{"key":"3138_CR134","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1371\/journal.pone.0050995","volume":"7","author":"SM Lok","year":"2012","unstructured":"Lok SM, Costin JM, Hrobowski YM et al (2012) Release of dengue virus genome induced by a peptide inhibitor. PLoS One 7:5\u201312. https:\/\/doi.org\/10.1371\/journal.pone.0050995","journal-title":"PLoS One"},{"key":"3138_CR135","doi-asserted-by":"publisher","first-page":"e721","DOI":"10.1371\/journal.pntd.0000721","volume":"4","author":"JM Costin","year":"2010","unstructured":"Costin JM, Jenwitheesuk E, Lok S-M et al (2010) Structural optimization and de novo design of dengue virus entry inhibitory peptides. PLoS Negl Trop Dis 4:e721. https:\/\/doi.org\/10.1371\/journal.pntd.0000721","journal-title":"PLoS Negl Trop Dis"},{"key":"3138_CR136","volume-title":"Human herpesviruses: biology, therapy, and immunoprophylaxis","author":"B Roizman","year":"2007","unstructured":"Roizman B, Taddeo B (2007) The strategy of herpes simplex virus replication and takeover of the host cell. In: Arvin A, Campadelli-Fiume G, Mocarski E et al (eds) Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge"},{"key":"3138_CR137","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1128\/aac.00793-08","volume":"53","author":"R Akkarawongsa","year":"2009","unstructured":"Akkarawongsa R, Pocaro NE, Case G et al (2009) Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection. Antimicrob Agents Chemother 53:987\u2013996. https:\/\/doi.org\/10.1128\/aac.00793-08","journal-title":"Antimicrob Agents Chemother"},{"key":"3138_CR138","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000464134","volume":"59","author":"A Cetina-Corona","year":"2016","unstructured":"Cetina-Corona A, L\u00f3pez-S\u00e1nchez U, Salinas-Trujano J et al (2016) Peptides derived from glycoproteins H and B of herpes simplex virus type 1 and herpes simplex virus type 2 are capable of blocking herpetic infection in vitro. Intervirology 59:235\u2013242. https:\/\/doi.org\/10.1159\/000464134","journal-title":"Intervirology"},{"key":"3138_CR139","unstructured":"ONUSIDA (2018) Global AIDS monitoring 2018: indicators for monitoring the 2016 United Nations Political Declaration on HIV and AIDS. Geneva\u00a0"},{"key":"3138_CR140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/jvi.00288-17","volume":"91","author":"H Chong","year":"2017","unstructured":"Chong H, Xue J, Xiong S et al (2017) A lipopeptide HIV-1\/2 fusion inhibitor with highly potent in vitro, ex vivo, and in vivo antiviral activity. J Virol 91:1\u201313. https:\/\/doi.org\/10.1128\/jvi.00288-17","journal-title":"J Virol"},{"key":"3138_CR141","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.1073\/pnas.0936469100","volume":"100","author":"P Lemey","year":"2003","unstructured":"Lemey P, Pybus OG, Wang B et al (2003) Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci 100:6588\u20136592. https:\/\/doi.org\/10.1073\/pnas.0936469100","journal-title":"Proc Natl Acad Sci"},{"key":"3138_CR142","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.antiviral.2013.12.001","volume":"102","author":"L Men\u00e9ndez-Arias","year":"2014","unstructured":"Men\u00e9ndez-Arias L, \u00c1lvarez M (2014) Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. Antiviral Res 102:70\u201386. https:\/\/doi.org\/10.1016\/j.antiviral.2013.12.001","journal-title":"Antiviral Res"},{"key":"3138_CR143","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1091\/mbc.e05-06-0496","volume":"16","author":"RM Markosyan","year":"2005","unstructured":"Markosyan RM (2005) Time-resolved imaging of HIV-1 env-mediated lipid and content mixing between a single virion and cell membrane. Mol Biol Cell 16:5502\u20135513. https:\/\/doi.org\/10.1091\/mbc.e05-06-0496","journal-title":"Mol Biol Cell"},{"key":"3138_CR144","doi-asserted-by":"publisher","first-page":"11126","DOI":"10.1074\/jbc.m800200200","volume":"283","author":"Y He","year":"2008","unstructured":"He Y, Xiao Y, Song H et al (2008) Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 283:11126\u201311134. https:\/\/doi.org\/10.1074\/jbc.m800200200","journal-title":"J Biol Chem"},{"key":"3138_CR145","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S0149-2918(04)90032-X","volume":"26","author":"HB Fung","year":"2004","unstructured":"Fung HB, Guo Y (2004) Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther 26:352\u2013378","journal-title":"Clin Ther"},{"key":"3138_CR146","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.sbi.2009.07.003","volume":"19","author":"F Naider","year":"2009","unstructured":"Naider F, Anglister J (2009) Peptides in the treatment of AIDS. Curr Opin Struct Biol 19:473\u2013482. https:\/\/doi.org\/10.1016\/j.sbi.2009.07.003","journal-title":"Curr Opin Struct Biol"},{"key":"3138_CR147","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1097\/qad.0b013e32835edc1d","volume":"27","author":"P Borrego","year":"2013","unstructured":"Borrego P, Calado R, Marcelino JM et al (2013) An ancestral HIV-2\/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity. AIDS 27:1081\u20131090. https:\/\/doi.org\/10.1097\/qad.0b013e32835edc1d","journal-title":"AIDS"},{"key":"3138_CR148","first-page":"254","volume":"38","author":"N Vincent","year":"2005","unstructured":"Vincent N, Tardy J-C, Livrozet J-M et al (2005) Depletion in antibodies targeted to the HR2 region of HIV-1 glycoprotein gp41 in sera of HIV-1-seropositive patients treated with T20. J Acquir Immune Defic Syndr 38:254\u2013262","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3138_CR149","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1128\/jvi.00373-15","volume":"89","author":"Y Su","year":"2015","unstructured":"Su Y, Chong H, Qiu Z et al (2015) Mechanism of HIV-1 resistance to short-peptide fusion inhibitors targeting the Gp41 pocket. J Virol 89:5801\u20135811. https:\/\/doi.org\/10.1128\/jvi.00373-15","journal-title":"J Virol"},{"key":"3138_CR150","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1128\/aac.01152-12","volume":"57","author":"F Brauer","year":"2013","unstructured":"Brauer F, Schmidt K, Zahn RC et al (2013) A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity. Antimicrob Agents Chemother 57:679\u2013688. https:\/\/doi.org\/10.1128\/aac.01152-12","journal-title":"Antimicrob Agents Chemother"},{"key":"3138_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0195744","volume":"13","author":"I B\u00e1rtolo","year":"2018","unstructured":"B\u00e1rtolo I, Diniz AR, Borrego P et al (2018) Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women. PLoS One 13:1\u201323. https:\/\/doi.org\/10.1371\/journal.pone.0195744","journal-title":"PLoS One"},{"key":"3138_CR152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/jvi.01839-16","volume":"91","author":"S Xiong","year":"2017","unstructured":"Xiong S, Borrego P, Ding X et al (2017) A helical short-peptide fusion inhibitor with highly potent activity against human immunodeficiency virus type 1 (HIV-1), HIV-2, and Simian immunodeficiency. Virus 91:1\u201315. https:\/\/doi.org\/10.1128\/jvi.01839-16","journal-title":"Virus"},{"key":"3138_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph9030053","volume":"9","author":"I Hsieh","year":"2016","unstructured":"Hsieh I, Hartshorn KL (2016) The role of antimicrobial peptides in influenza virus infection and their potential as antiviral and immunomodulatory therapy. Pharmaceuticals 9:1\u201315. https:\/\/doi.org\/10.3390\/ph9030053","journal-title":"Pharmaceuticals"},{"key":"3138_CR154","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1056\/nejmoa0903810","volume":"360","author":"FS Dawood","year":"2009","unstructured":"Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S et al (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360:2605\u20132615. https:\/\/doi.org\/10.1056\/nejmoa0903810","journal-title":"N Engl J Med"},{"key":"3138_CR155","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/irv.12446","volume":"11","author":"P Koszalka","year":"2017","unstructured":"Koszalka P, Tilmanis D, Hurt AC (2017) Influenza antivirals currently in late-phase clinical trial. Influenza Other Respi Viruses 11:240\u2013246. https:\/\/doi.org\/10.1111\/irv.12446","journal-title":"Influenza Other Respi Viruses"},{"key":"3138_CR156","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/med.21289","volume":"34","author":"E Vanderlinden","year":"2014","unstructured":"Vanderlinden E, Naesens L (2014) Emerging antiviral strategies to interfere with influenza virus entry. Med Res Rev 34:301\u2013339. https:\/\/doi.org\/10.1002\/med.21289","journal-title":"Med Res Rev"},{"key":"3138_CR157","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.bcp.2017.07.023","volume":"144","author":"D Lin","year":"2017","unstructured":"Lin D, Luo Y, Yang G et al (2017) Potent influenza A virus entry inhibitors targeting a conserved region of hemagglutinin. Biochem Pharmacol 144:35\u201351. https:\/\/doi.org\/10.1016\/j.bcp.2017.07.023","journal-title":"Biochem Pharmacol"},{"key":"3138_CR158","doi-asserted-by":"publisher","first-page":"e76876","DOI":"10.1371\/journal.pone.0076876","volume":"8","author":"R L\u00f3pez-Mart\u00ednez","year":"2013","unstructured":"L\u00f3pez-Mart\u00ednez R, Ram\u00edrez-Salinas GL, Correa-Basurto J, Barr\u00f3n BL (2013) Inhibition of influenza A virus infection in vitro by peptides designed in silico. PLoS One 8:e76876. https:\/\/doi.org\/10.1371\/journal.pone.0076876","journal-title":"PLoS One"},{"key":"3138_CR159","doi-asserted-by":"publisher","first-page":"e1005409","DOI":"10.1371\/journal.ppat.1005409","volume":"12","author":"MT Koday","year":"2016","unstructured":"Koday MT, Nelson J, Chevalier A et al (2016) A computationally designed hemagglutinin stem-binding protein provides in vivo protection from influenza independent of a host immune response. PLoS Pathogens 12:e1005409. https:\/\/doi.org\/10.1371\/journal.ppat.1005409","journal-title":"PLoS Pathogens"},{"key":"3138_CR160","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/v10100515","volume":"10","author":"N Friedman","year":"2018","unstructured":"Friedman N, Alter H, Hindiyeh M et al (2018) Human coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU1. Viruses 10:515. https:\/\/doi.org\/10.3390\/v10100515","journal-title":"Viruses"},{"key":"3138_CR161","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1126\/science.1092002","volume":"303","author":"Chinese SARS Molecular Epidemiology Consortium TCSME","year":"2004","unstructured":"Chinese SARS Molecular Epidemiology Consortium TCSME (2004) Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 303:1666\u20131669. https:\/\/doi.org\/10.1126\/science.1092002","journal-title":"Science"},{"key":"3138_CR162","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jhin.2016.10.008","volume":"95","author":"KH Kim","year":"2017","unstructured":"Kim KH, Tandi TE, Choi JW et al (2017) Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications. J Hosp Infect 95:207\u2013213. https:\/\/doi.org\/10.1016\/j.jhin.2016.10.008","journal-title":"J Hosp Infect"},{"key":"3138_CR163","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/s0140-6736(15)60454-8","volume":"386","author":"A Zumla","year":"2015","unstructured":"Zumla A, Hui DS, Perlman S (2015) Middle East respiratory syndrome. Lancet 386:995\u20131007. https:\/\/doi.org\/10.1016\/s0140-6736(15)60454-8","journal-title":"Lancet"},{"key":"3138_CR164","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.bbrc.2006.04.141","volume":"345","author":"C Liu","year":"2006","unstructured":"Liu C, Feng Y, Gao F et al (2006) Characterization of HCoV-229E fusion core: implications for structure basis of coronavirus membrane fusion. Biochem Biophys Res Commun 345:1108\u20131115. https:\/\/doi.org\/10.1016\/j.bbrc.2006.04.141","journal-title":"Biochem Biophys Res Commun"},{"key":"3138_CR165","doi-asserted-by":"publisher","first-page":"13134","DOI":"10.1128\/jvi.02433-13","volume":"87","author":"J Gao","year":"2013","unstructured":"Gao J, Lu G, Qi J et al (2013) Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of middle east respiratory syndrome coronavirus. J Virol 87:13134\u201313140. https:\/\/doi.org\/10.1128\/jvi.02433-13","journal-title":"J Virol"},{"key":"3138_CR166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms4067","volume":"5","author":"L Lu","year":"2014","unstructured":"Lu L, Liu Q, Zhu Y et al (2014) Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 5:1\u201312. https:\/\/doi.org\/10.1038\/ncomms4067","journal-title":"Nat Commun"},{"key":"3138_CR167","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/v9090255","volume":"9","author":"Y Sun","year":"2017","unstructured":"Sun Y, Zhang H, Shi J et al (2017) Identification of a novel inhibitor against Middle East respiratory syndrome coronavirus. Viruses 9:255. https:\/\/doi.org\/10.3390\/v9090255","journal-title":"Viruses"},{"key":"3138_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms19020487","volume":"19","author":"S Xia","year":"2018","unstructured":"Xia S, Xu W, Wang Q et al (2018) Peptide-based membrane fusion inhibitors targeting HCoV-229E spike protein HR1 and HR2 domains. Int J Mol Sci 19:1\u201315. https:\/\/doi.org\/10.3390\/ijms19020487","journal-title":"Int J Mol Sci"},{"key":"3138_CR169","doi-asserted-by":"crossref","unstructured":"Fields GB (2001) Introduction to Peptide Synthesis. In: Current Protocols in Protein Science. John Wiley & Sons, Inc., Hoboken, NJ, USA, pp 18.1.1\u201318.1.9","DOI":"10.1002\/0471140864.ps1801s26"},{"key":"3138_CR170","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature10702","volume":"480","author":"VR Pattabiraman","year":"2011","unstructured":"Pattabiraman VR, Bode JW (2011) Rethinking amide bond synthesis. Nature 480:471\u2013479. https:\/\/doi.org\/10.1038\/nature10702","journal-title":"Nature"},{"key":"3138_CR171","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","volume":"17","author":"L Di","year":"2014","unstructured":"Di L (2014) Strategic approaches to optimizing peptide ADME properties. AAPS J 17:134\u2013143. https:\/\/doi.org\/10.1208\/s12248-014-9687-3","journal-title":"AAPS J"},{"key":"3138_CR172","doi-asserted-by":"publisher","first-page":"33913","DOI":"10.1074\/jbc.m204928200","volume":"277","author":"N Papo","year":"2002","unstructured":"Papo N, Oren Z, Pag U et al (2002) The consequence of sequence alteration of an amphipathic a\u2014helical antimicrobial peptide and its diastereomers. J Biol Chem 277:33913\u201333921. https:\/\/doi.org\/10.1074\/jbc.m204928200","journal-title":"J Biol Chem"},{"key":"3138_CR173","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/17425247.2017.1360863","volume":"15","author":"D Lembo","year":"2018","unstructured":"Lembo D, Donalisio M, Civra A et al (2018) Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections. Expert Opin Drug Deliv 15:93\u2013114. https:\/\/doi.org\/10.1080\/17425247.2017.1360863","journal-title":"Expert Opin Drug Deliv"},{"key":"3138_CR174","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jconrel.2016.03.025","volume":"229","author":"S Ron-Doitch","year":"2016","unstructured":"Ron-Doitch S, Sawodny B, K\u00fchbacher A et al (2016) Reduced cytotoxicity and enhanced bioactivity of cationic antimicrobial peptides liposomes in cell cultures and 3D epidermis model against HSV. J Control Release 229:163\u2013171. https:\/\/doi.org\/10.1016\/j.jconrel.2016.03.025","journal-title":"J Control Release"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-019-03138-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-019-03138-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-019-03138-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T01:48:39Z","timestamp":1744163319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-019-03138-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":174,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2019,9,1]]}},"alternative-id":["3138"],"URL":"https:\/\/doi.org\/10.1007\/s00018-019-03138-w","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735786825.793575251","asserted-by":"object"}]},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,17]]},"assertion":[{"value":"21 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}